» Articles » PMID: 22609537

Age and Gender Dependent Bioavailability of R- and R,S-α-lipoic Acid: a Pilot Study

Overview
Journal Pharmacol Res
Publisher Elsevier
Specialty Pharmacology
Date 2012 May 22
PMID 22609537
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Lipoic acid (LA) shows promise as a beneficial micronutrient toward improving elder health. Studies using old rats show that (R)-α-LA (R-LA) significantly increases low molecular weight antioxidants that otherwise decline with age. Despite this rationale for benefiting human health, little is known about age-associated alterations in absorption characteristics of LA, or whether the commercially available racemic mixture of LA (R,S-LA) is equally as bioavailable as the naturally occurring R-enantiomer. To address these discrepancies, a pilot study was performed to establish which form of LA is most effectively absorbed in older subjects relative to young volunteers. Young adults (average age=32 years) and older adults (average age=79 years) each received 500 mg of either R- or R,S-LA. Blood samples were collected for 3h after supplementation. After a washout period they were given the other chiral form of LA not originally ingested. Results showed that 2 out of 6 elder males exhibited greater maximal plasma LA and area under the curve for the R-form of LA versus the racemic mixture. The elder subjects also demonstrated a reduced time to reach maximal plasma LA concentration following R-LA supplementation than for the racemic mixture. In contrast, young males had a tendency for increased bioavailability of R,S-LA. Overall, bioavailability for either LA isoform was much more variable between older subjects compared to young adults. Plasma glutathione levels were not altered during the sampling period. Thus subject age, and potential for varied response, should be considered when determining an LA supplementation regimen.

Citing Articles

Nanotechnological Approaches to Enhance the Potential of α-Lipoic Acid for Application in the Clinic.

Bellini C, Mancin F, Papini E, Tavano R Antioxidants (Basel). 2024; 13(6).

PMID: 38929145 PMC: 11201002. DOI: 10.3390/antiox13060706.


Molecular and Therapeutic Insights of Alpha-Lipoic Acid as a Potential Molecule for Disease Prevention.

Tripathi A, Ray A, Mishra S, Mall Bishen S, Mishra H, Khurana A Rev Bras Farmacogn. 2023; 33(2):272-287.

PMID: 36778891 PMC: 9904877. DOI: 10.1007/s43450-023-00370-1.


Lipoic acid. Kinetics and pluripotent biological properties and derivatives.

Theodosis-Nobelos P, Papagiouvannis G, Tziona P, Rekka E Mol Biol Rep. 2021; 48(9):6539-6550.

PMID: 34420148 DOI: 10.1007/s11033-021-06643-z.


A systematic review of treatment for patients with burning mouth syndrome.

Tan H, Smith J, Hoffmann J, Renton T Cephalalgia. 2021; 42(2):128-161.

PMID: 34404247 PMC: 8793318. DOI: 10.1177/03331024211036152.


Mechanics Insights of Alpha-Lipoic Acid against Cardiovascular Diseases during COVID-19 Infection.

Rochette L, Ghibu S Int J Mol Sci. 2021; 22(15).

PMID: 34360751 PMC: 8348748. DOI: 10.3390/ijms22157979.


References
1.
Tastekin N, Aydogdu N, Dokmeci D, Usta U, Birtane M, Erbas H . Protective effects of L-carnitine and alpha-lipoic acid in rats with adjuvant arthritis. Pharmacol Res. 2007; 56(4):303-10. DOI: 10.1016/j.phrs.2007.07.008. View

2.
Mignini F, Capacchietti M, Napolioni V, Reggiardo G, Fasani R, Ferrari P . Single dose bioavailability and pharmacokinetic study of a innovative formulation of α-lipoic acid (ALA600) in healthy volunteers. Minerva Med. 2011; 102(6):475-82. View

3.
Donner A . Approaches to sample size estimation in the design of clinical trials--a review. Stat Med. 1984; 3(3):199-214. DOI: 10.1002/sim.4780030302. View

4.
Devasagayam T, Subramanian M, Pradhan D, Sies H . Prevention of singlet oxygen-induced DNA damage by lipoate. Chem Biol Interact. 1993; 86(1):79-92. DOI: 10.1016/0009-2797(93)90113-d. View

5.
Suh J, Wang H, Liu R, Liu J, Hagen T . (R)-alpha-lipoic acid reverses the age-related loss in GSH redox status in post-mitotic tissues: evidence for increased cysteine requirement for GSH synthesis. Arch Biochem Biophys. 2004; 423(1):126-35. PMC: 4696556. DOI: 10.1016/j.abb.2003.12.020. View